AnaptysBio ANAB Stock
AnaptysBio Price Chart
AnaptysBio ANAB Financial and Trading Overview
| AnaptysBio stock price | 49.2 USD |
| Previous Close | 48.53 USD |
| Open | 48.53 USD |
| Bid | 35.64 USD x 200 |
| Ask | 60.95 USD x 200 |
| Day's Range | 47.56 - 49.84 USD |
| 52 Week Range | 19.65 - 72.36 USD |
| Volume | 595.55K USD |
| Avg. Volume | 574K USD |
| Market Cap | 1.47B USD |
| Beta (5Y Monthly) | 0.452 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 87.25 USD |
ANAB Valuation Measures
| Enterprise Value | 1.58B USD |
| Trailing P/E | N/A |
| Forward P/E | 9.707435 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.864396 |
| Price/Book (mrq) | 138.20224 |
| Enterprise Value/Revenue | 14.858 |
| Enterprise Value/EBITDA | 23.987 |
Trading Information
AnaptysBio Stock Price History
| Beta (5Y Monthly) | 0.452 |
| 52-Week Change | 140.64% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 72.36 USD |
| 52 Week Low | 19.65 USD |
| 50-Day Moving Average | 54.98 USD |
| 200-Day Moving Average | 48.8 USD |
ANAB Share Statistics
| Avg. Volume (3 month) | 574K USD |
| Avg. Daily Volume (10-Days) | 638.89K USD |
| Shares Outstanding | 29.9M |
| Float | 20.44M |
| Short Ratio | 12.32 |
| % Held by Insiders | 5.62% |
| % Held by Institutions | 105.12% |
| Shares Short | 5.44M |
| Short % of Float | 40.51% |
| Short % of Shares Outstanding | 18.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 15:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 246.95% |
| Operating Margin (ttm) | 53.38% |
| Gross Margin | 105.03% |
| EBITDA Margin | 61.94% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 106.09M USD |
| Revenue Per Share (ttm) | 3.66 USD |
| Quarterly Revenue Growth (yoy) | 23.50% |
| Gross Profit (ttm) | 111.42M USD |
| EBITDA | 65.71M USD |
| Net Income Avi to Common (ttm) | 352.72M USD |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 164.14M USD |
| Total Cash Per Share (mrq) | 5.49 USD |
| Total Debt (mrq) | 269.59M USD |
| Total Debt/Equity (mrq) | 2546.89 USD |
| Current Ratio (mrq) | 5.613 |
| Book Value Per Share (mrq) | 0.356 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -105118000 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of AnaptysBio
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10770 Wateridge Circle |
| ZIP | 92121 |
| Phone | 858 362 6295 |
| Website | https://www.anaptysbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Q&A For AnaptysBio Stock
What is a current ANAB stock price?
AnaptysBio ANAB stock price today per share is 49.2 USD.
How to purchase AnaptysBio stock?
You can buy ANAB shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AnaptysBio?
The stock symbol or ticker of AnaptysBio is ANAB.
Which industry does the AnaptysBio company belong to?
The AnaptysBio industry is Biotechnology.
How many shares does AnaptysBio have in circulation?
The max supply of AnaptysBio shares is 29.9M.
What is AnaptysBio Price to Earnings Ratio (PE Ratio)?
AnaptysBio PE Ratio is now.
What was AnaptysBio earnings per share over the trailing 12 months (TTM)?
AnaptysBio EPS is -0.96 USD over the trailing 12 months.
Which sector does the AnaptysBio company belong to?
The AnaptysBio sector is Healthcare.
AnaptysBio ANAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27477.31 USD — |
+1.05
|
7.04B USD — | 27223.49 USD — | 27544.06 USD — | — - | 7.04B USD — |
|
US Tech Biotechnology
NBI
US
|
7022.12 USD — |
+1.07
|
— — | 6892.36 USD — | 7043.1 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1320 USD — |
+1.33
|
— — | 1298.21 USD — | 1322.56 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13524.02 USD — |
+1.07
|
— — | 13397.04 USD — | 13557.29 USD — | — - | — — |
- {{ link.label }} {{link}}
